The impact of azacitidine on improvement of quality of life in patients in venerable age with intermediate-2 risk group of myelodysplastic syndrome

Abstract

For elderly patients with myelodysplastic syndrome (MDS) the improvement of the quality of life is one of the most important aspects of the treatment, with the particular role of becoming transfusion independent. Currently, the median age of onset for the MDS in Poland is 71-years-old. In Europe we are observing the constant ageing of the population, which leads to the increase in the incidence of MDS in elderly patients, who are very often encumbered with comorbidities. In the coming 50 years the 4-fold rise of the people above 85 years is expected to be observed, which will be paired with the inceased of MDS cases. This paper describes a patient with MDS treated with azacitidine. After 4 cycles of hypomethylating agents treatment patient became tranfusion independent. Treat­ment was continued for 19 cycles. After 6 cycles complete remission has been achieved.